Rhythm Pharmaceuticals Inc.

NASDAQ:RYTM 4:00:00 PM EDT

38.15

-1.56 (-3.93%)

6:11:41 PM EDT: $39.50 +1.35 (+3.54%)

Market Cap (Intraday)	2.29B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$27.69 Million
Adjusted EPS	-$2.35

See more estimates

10-Day MA	$39.31
50-Day MA	$41.98
200-Day MA	$33.68

See more pivots

Rhythm Pharmaceuticals Inc. Stock, NASDAQ:RYTM

222 Berkeley Street, 12th floor, Boston, Massachusetts 02116-3748

United States of America

Phone: +1.857.264.4280

Number of Employees: 226

http://www.rhythmtx.com

Description

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.